AEDG comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-02. Numbers and descriptions here follow the published literature rather than marketing material.
Several names circulate for the same molecule, including epitalon, epithalone, epithalamin tetrapeptide, and the sequence code AEDG. A CAS registry number, 307297-39-8, is commonly cited for it, though catalogue entries should be checked against supplier documentation because mislabelled records occur. In its usual form the peptide carries free amino and carboxyl termini and is neither glycosylated nor lipidated. Researchers distinguish the defined tetrapeptide from epithalamin itself, a crude pineal preparation containing many peptides that is not chemically characterised.
Material supplied for laboratory use is normally a lyophilised white to off-white powder that dissolves readily in water and in isotonic saline. Lyophilised cakes are hygroscopic and should be equilibrated to room temperature before opening to limit condensation on the solid. Solutions are typically prepared at milligram-per-millilitre concentrations and divided into single-use aliquots, because repeated freeze–thaw cycles degrade short peptides. Aqueous solutions are far less stable than the dry powder, and identity is usually verified by mass spectrometry alongside purity estimation from reversed-phase high-performance liquid chromatography.
Epitalon is a synthetic linear tetrapeptide with the sequence alanine–glutamate–aspartate–glycine, abbreviated AEDG. Its molecular formula is C14H22N4O9 and the calculated mass is approximately 390.35 g/mol. The compound is made by solid-phase peptide synthesis rather than extracted from tissue, although early work described it as a short fragment of a peptide fraction obtained from bovine pineal extract. In the research literature the spelling epitalon and the variant epithalone both appear, while AEDG is the standard code used in peptide nomenclature.
Published work on this compound consists mainly of in vitro experiments, animal studies, and small clinical investigations, a substantial share of which appeared in Russian-language journals. Sample sizes are generally small, control conditions differ between studies, and several endpoints rely on markers whose clinical meaning is itself debated. Reviews of the longevity field treat the peptide as an early example of telomerase-directed research rather than an established intervention. Regulatory treatment varies by country: some jurisdictions place it under prescription controls, others treat it as a laboratory material, and importation may be restricted regardless of local status.
Epitalon is a synthetic tetrapeptide whose sequence is alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. It was developed in Russia during the 1980s and 1990s by investigators associated with the St. Petersburg Institute of Bioregulation and Gerontology, who studied short peptides as regulators of gene expression and tissue function. The alternative spelling epithalon appears interchangeably in the literature, and the two names refer to the same molecule. Outside Russia it is encountered chiefly as a research chemical rather than a licensed medicine, and it holds no approval from the United States Food and Drug Administration or the European Medicines Agency.
| Property | Value | Notes |
|---|---|---|
| Amino acid sequence | Ala-Glu-Asp-Gly | Linear tetrapeptide, also written AEDG |
| Molecular mass | About 390.35 g/mol | Value calculated from the sequence |
| Appearance | White to off-white powder | Lyophilised material forms a loose cake |
| Solubility | Freely soluble in water | Also dissolves in isotonic saline |
| Storage | -20 °C, desiccated | Aliquot solutions to avoid freeze–thaw cycling |
The compound is generally described as a synthetic analogue of a fragment isolated from a pineal gland extract. Researchers associated with the Saint Petersburg Institute of Bioregulation and Gerontology introduced it during the 1980s and 1990s while studying short peptides from animal tissue. The original extract, called epithalamin, is a heterogeneous mixture, whereas epitalon is a single defined sequence. That distinction matters because findings reported for the extract are not automatically findings about the pure tetrapeptide, and claims about broader biological effects remain a separate question from the chemical identity described here.
Residue composition is the property that most cleanly separates verified material from mislabelled samples. Alanine, glutamate, aspartate and glycine appear in that order from the N-terminus, and the two acidic residues sit in the middle of the chain. Because the peptide is short, it can be produced by solid-phase synthesis and characterised by mass spectrometry without ambiguity. Any reported sample whose measured mass departs substantially from 390 daltons is a different compound or a degraded mixture rather than epitalon.
Epitalon is a synthetic tetrapeptide whose sequence is alanine-glutamate-aspartate-glycine, written in single-letter code as AEDG. The four residues are joined by three peptide bonds, giving a linear backbone with no branching and no disulfide bridges. Its calculated molecular mass for the free form is approximately 390.3 daltons, a figure that rises when the compound is supplied as an acetate or trifluoroacetate salt. Because the chain is short, the molecule is defined entirely by its residue order rather than by any folded three-dimensional structure.
The compound is described in the literature as a derivative of epithalamin, a preparation obtained from bovine pineal tissue. Work on this peptide family was carried out mainly by a research group in Saint Petersburg beginning in the 1980s, and the substance was later registered for clinical use in Russia under the name Epitalon. Outside that region it is generally treated as a research chemical rather than an approved medicine. Statements about its biological activity rest on a relatively small number of studies, and independent replication remains limited.
The human musculoskeletal system (also known as the human locomotor system, and previously the activity system) is an organ system that gives humans the ability to move using their muscular and skeletal systems. The musculoskeletal system provides form, support, stability, and movement to the body. The human musculoskeletal system is made up of the bones of the skeleton, muscles, cartilage, tendons, ligaments, joints, and other connective tissue that supports and binds tissues and organs together. The musculoskeletal system's primary functions include supporting the body, allowing motion, and protecting vital organs. The skeletal portion of the system serves as the main storage system for calcium and phosphorus and contains critical components of the hematopoietic system. This system describes how bones are connected to other bones and muscle fibers via connective tissue such as tendons and ligaments. The bones provide stability to the body. Muscles keep bones in place and also play a role in their movement. To allow motion, different bones form joints together. Cartilage prevents the bone ends from rubbing directly onto each other. Muscles contract to move the bones attached at the joint. The joints and muscles are designed to interact harmoniously so that any applied muscular force keeps the joint positioned and aligned correctly during movement and this, reciprocally, helps to maintain the correct length and tension in those corresponding muscles. There are, however, diseases and disorders that may adversely affect the function and overall effectiveness of the system.
=== Phosphoenolpyruvate carboxykinase === Mitochondrial phosphoenolpyruvate carboxykinase is thought to participate in the transfer of the phosphorylation potential from the matrix to the cytosol and vice versa. However, it is strongly favored towards GTP hydrolysis, thus it is not really considered as an important source of intra-mitochondrial substrate-level phosphorylation.
In 1974, Torbert left NRPS; he and Matthew Kelly co-founded the band Kingfish (best known for Bob Weir's membership during the Grateful Dead's late-1974 to mid-1976 touring hiatus) the year before. Initially he was replaced by Skip Battin (formerly of Skip & Flip and the early 1970s lineup of The Byrds), who briefly emerged as the dominant creative force in the band due to his prolific songwriting collaboration with controversial Hollywood impresario Kim Fowley. Stephen A. Love of Rick Nelson's Stone Canyon Band and the Roger McGuinn Band replaced Battin after he left the group to co-found a reconstituted lineup of The Flying Burrito Brothers in 1976. Shortly thereafter, Spencer Dryden relinquished his performance duties to manage the group in 1977. His musical replacement was Patrick Shanahan. Allen Kemp joined on bass in 1978 before emerging as a co-frontman on guitar and vocals, contributing prominently to the songwriting for the band's last major label release, 1981's Feelin' All Right. In 1982, Nelson and Cage left the band, leaving Dawson as the sole remaining member from the classic lineup.
==== Dental and other post-surgical pain ==== Pain after a dental surgery provides a reliable model for the action of analgesics on other kinds of acute pain. For the relief of such pain, paracetamol is inferior to ibuprofen. Full therapeutic doses of nonsteroidal anti-inflammatory drugs (NSAIDs) ibuprofen, naproxen, or diclofenac are clearly more efficacious than the paracetamol/codeine combination which is frequently prescribed for dental pain. The combinations of paracetamol and NSAIDs ibuprofen or diclofenac are promising, possibly offering better pain control than either paracetamol or the NSAID alone. Additionally, the paracetamol/ibuprofen combination may be superior to paracetamol/codeine and ibuprofen/codeine combinations. A meta-analysis of general post-surgical pain, which included dental and other surgery, showed the paracetamol/codeine combination to be more effective than paracetamol alone: it provided significant pain relief to as much as 53% of the participants, while the placebo helped only 7%.
Al-Qaeda leader Osama bin Laden, who went into hiding in the White Mountains, was targeted by U.S. coalition forces in the Battle of Tora Bora, but he escaped across the Pakistani border and remained out of sight for almost ten years. In an interview with Tayseer Allouni on October 21, 2001, bin Laden stated: The events proved the extent of terrorism that America exercises in the world. Bush stated that the world has to be divided in two: Bush and his supporters, and any country that doesn't get into the global crusade is with the terrorists. What terrorism is clearer than this? Many governments were forced to support this "new terrorism"... America wouldn't live in security until we live it truly in Palestine. This showed the reality of America, which puts Israel's interest above its own people's interest. America won't get out of this crisis until it gets out of the Arabian Peninsula, and until it stops its support of Israel.
Sources: en.wikipedia.org
{\displaystyle h{{\left[{\frac {\mu _{v}^{2}}{g{{\rho }_{v}}\left({{\rho }_{L}}-{{\rho }_{v}}\right)k_{v}^{3}}}\right]}^{{}^{1}\!\!\diagup \!\!{}_{3}\;}}=0.0020{{\left[{\frac {4m}{\pi {{D}_{v}}{{\mu }_{v}}}}\right]}^{0.6}}}
BRD-6929 is a selective inhibitor of HDAC1 and HDAC2, with IC50Tooltip half-maximal inhibitory concentration values of 1 nM and 8–30 nM, respectively, and with 30- to 400-fold selectivity over HDAC3 (IC50 = 398–458 nM) and no inhibition of HDAC8 or class II HDACs (IC50 = >30,000 nM). However, although originally reported to be selective for inhibition of HDAC1 and HDAC2 over HDAC3, subsequent research has found that BRD-6929 is not in fact selective over HDAC3, with previous findings being claimed to have been an assay artifact. As a result, BRD-6929 is no longer recommended as a selective HDAC1 and HDAC2 inhibitor. The drug shows slow-on/slow-off binding kinetics and hence more sustained HDAC inhibition, unlike other HDAC inhibitors like the fast-on/fast-off vorinostat (SAHA) and entinostat (MS-275). Aside from the HDACs, it also showed no binding at 80 other targets at a concentration of 10,000 nM. BRD-6929 produces antidepressant-like and mood-stabilizing-like effects in rodents. This included reducing immobility in the forced swim test (FST) and attenuating amphetamine-induced hyperlocomotion without affecting basal locomotor activity. Conversely, vorinostat was ineffective in these tests. In addition, vorinostat showed dissimilar and lesser effects on gene transcription compared to BRD-6929. These differences may be related to selectivity and duration of exposure, with sustained exposure as with BRD-6929 possibly being advantageous.
Osedax antarcticus Glover, Wiklund & Dahlgren, 2013 Osedax bozoi Berman, Hiley, Read & Rouse, 2024 Osedax braziliensis Fujiwara, Jimi, Sumida, Kawato, Kitazato Osedax bryani Rouse, Goffredi, Johnson & Vrijenhoek Osedax byronbayensis Georgieva, Wiklund, Ramos, Neal, Glasby & Gunton, 2023 Osedax craigmcclaini Berman, Hiley, Read, Rouse, 2024 Osedax crouchi Amon, Wiklund, Dahlgren, Copley, Smith, Jamieson & Glover, 2014 Osedax deceptionensis Taboada, Cristobo, Avila, Wiklund & Glover, 2013 Osedax docricketts Rouse, Goffredi, Johnson & Vrijenhoek Osedax estcourti Berman, Hiley, Read & Rouse, 2024 Osedax fenrisi Eilertsen, Dahlgren & Rapp, 2020 Osedax frankpressi Rouse, Goffredi & Vrijenhoek, 2004 Osedax jabba Rouse, Goffredi, Johnson & Vrijenhoek Osedax japonicus Fujikura, Fujiwara & Kawato, 2006 Osedax knutei Rouse, Goffredi, Johnson & Vrijenhoek Osedax lehmani Rouse, Goffredi, Johnson & Vrijenhoek Osedax lonnyi Rouse, Goffredi, Johnson & Vrijenhoek Osedax mucofloris Glover, Kallstrom, Smith & Dahlgren, 2005 Osedax nataliae Gularte, Sumida, Bergamo & Rouse, 2024 Osedax nordenskjoeldi Amon, Wiklund, Dahlgren, Copley, Smith, Jamieson & Glover, 2014 Osedax priapus Rouse et al., 2014 Osedax packardorum Rouse, Goffredi, Johnson & Vrijenhoek Osedax randyi Rouse, Goffredi, Johnson & Vrijenhoek Osedax rogersi Amon, Wiklund, Dahlgren, Copley, Smith, Jamieson & Glover, 2014 Osedax roseus Rouse, Worsaae, Johnson, Jones & Vrijenhoek, 2008 Osedax rubiplumus Rouse, Goffredi & Vrijenhoek, 2004 Osedax ryderi Rouse, Goffredi, Johnson & Vrijenhoek Osedax sigridae Rouse, Goffredi, Johnson & Vrijenhoek Osedax talkovici Rouse, Goffredi, Johnson & Vrijenhoek Osedax tiburon Rouse, Goffredi, Johnson & Vrijenhoek Osedax traceyae Berman, Hiley, Read & Rouse, 2024 Osedax ventana Rouse, Goffredi, Johnson & Vrijenhoek Osedax waadjum Georgieva, Wiklund, Ramos, Neal, Glasby & Gunton, 2023 Osedax westernflyer Rouse, Goffredi, Johnson & Vrijenhoek
=== Capital increase and IPO === In October 2018, Dutch Bros received an undisclosed amount from private equity firm TSG Consumer Partners for a minority stake in the company and announced plans to expand to 800 stores over the next five years. Dutch Bros reported revenues of $238 million in 2019, $327.4 million in 2020, and $228 million over the first six months of 2021, heading into the company formally filing for its initial public offering (IPO) in August 2021. The company stated in its filing that it hoped to raise $100 million, which it would use toward paying down $192 million in long-term debt. Dutch Bros held its IPO and began trading on the New York Stock Exchange with the ticker symbol "BROS" on September 15, 2021. The IPO raised $484 million, selling about 21 million shares for $23 each. Travis Boersma retained about 74% of shareholder voting power after the listing, due to his ownership of class B stock before he sold his stake in November 2025.
Sources: en.wikipedia.org
It is a synthetic tetrapeptide. Its sequence was derived from research on peptide fractions of bovine pineal extract, and the intact AEDG sequence has not been demonstrated as an abundant free peptide in human tissue.
AEDG is the one-letter code for the four amino acids alanine, glutamate, aspartate and glycine in that order. The same molecule is written in three-letter form as Ala-Glu-Asp-Gly.
Identity is normally confirmed by mass spectrometry against the calculated mass of roughly 390.35 g/mol. Purity is then estimated by reversed-phase high-performance liquid chromatography with ultraviolet detection.
Epitalon is a synthetic four-amino-acid peptide with the sequence alanine–glutamate–aspartate–glycine, also written AEDG. It was developed in Russian gerontology research and is studied for proposed effects on telomerase, melatonin regulation, and neuroendocrine function. It is not an approved pharmaceutical in the United States or the European Union.